These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17379006)

  • 1. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
    Forst T; Pfützner A; Lübben G; Weber M; Marx N; Karagiannis E; Koehler C; Baurecht W; Hohberg C; Hanefeld M
    Metabolism; 2007 Apr; 56(4):491-6. PubMed ID: 17379006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.
    Pfützner A; Hanefeld M; Lübben G; Weber MM; Karagiannis E; Köhler C; Hohberg C; Forst T
    Horm Metab Res; 2007 Oct; 39(10):764-8. PubMed ID: 17952841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
    Pfützner A; Schöndorf T; Hanefeld M; Lübben G; Kann PH; Karagiannis E; Wilhelm B; Forst T
    Horm Metab Res; 2009 Mar; 41(3):202-6. PubMed ID: 19224430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance.
    Schaalan MF
    J Immunotoxicol; 2012; 9(2):201-9. PubMed ID: 22428554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.
    Forst T; Weber MM; Löbig M; Lehmann U; Müller J; Hohberg C; Friedrich C; Fuchs W; Pfützner A
    Clin Sci (Lond); 2010 Jul; 119(8):345-51. PubMed ID: 20509857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
    Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
    Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T
    Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.
    Pfützner A; Forst T
    J Diabetes Sci Technol; 2011 May; 5(3):784-93. PubMed ID: 21722594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes.
    Khan M; Murray FT; Karunaratne M; Perez A
    Diabetes Obes Metab; 2006 Jan; 8(1):31-8. PubMed ID: 16367880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
    Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
    Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
    Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.
    Li Y; Xie QH; You HZ; Tian J; Hao CM; Lin SY; Zhu TY
    Perit Dial Int; 2012; 32(5):507-15. PubMed ID: 22383630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.